688763-64-6|Elubrixin free base|1-(4-chloro-2-hydroxy-3-(piperazin-1-ylsulfonyl)phenyl)-3-(2-chloro-3-fluorophenyl)urea|-范德生物科技公司

Elubrixin free base

NMR下载 COA and HPLC MSDS下载
names：
1-(4-chloro-2-hydroxy-3-(piperazin-1-ylsulfonyl)phenyl)-3-(2-chloro-3-fluorophenyl)urea
CAS号：
688763-64-6
MDL Number：
MF(分子式)： C17H17Cl2FN4O4S MW(分子量)： 463.3054
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Elubrixin free base
英文别名	SB-656933; SB 656933; SB656933; SB-656933-AAF; SB-656933 AAF; SB-656933AAF; Elubrixin
CAS号	688763-64-6
Inchi	InChI=1S/C17H17Cl2FN4O4S/c18-10-4-5-13(23-17(26)22-12-3-1-2-11(20)14(12)19)15(25)16(10)29(27,28)24-8-6-21-7-9-24/h1-5,21,25H,6-9H2,(H2,22,23,26)
InchiKey	YQYFEGTYCUQBEI-UHFFFAOYSA-N
分子式 Formula	C17H17Cl2FN4O4S
分子量 Molecular Weight	463.3054
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Elubrixin free base(CAS:688763-64-6 ):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Elubrixin, also known as SB-656933 or SB-656933-AAF, is a interleukin 8 inhibitor and CXCR2 selective antagonist, which is potentially useful for Inflammatory bowel disease therapies. Elubrixin inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. demonstrates dose-dependent effects on neutrophil activation and recruitment within a well-tolerated dose range. SB-656933 may be an effective agent in neutrophil-predominant diseases.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Kaur M, Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonarydisease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. JPharmacol Exp Ther. 2013 Oct;347(1):173-80. doi: 10.1124/jpet.112.201855. Epub2013 Aug 2. PubMed PMID: 23912333.

[2]Moss RB, Mistry SJ, Konstan MW, Pilewski JM, Kerem E, Tal-Singer R, Lazaar AL;CF2110399 Investigators. Safety and early treatment effects of the CXCR2antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros. 2013May;12(3):241-8. doi: 10.1016/j.jcf.2012.08.016. Epub 2012 Sep 17. PubMed PMID:22995323.

[3] Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D. LPS challenge inhealthy subjects: an investigation of neutrophil chemotaxis mechanisms involvingCXCR1 and CXCR2. Int Immunopharmacol. 2012 Jul;13(3):225-31. doi:10.1016/j.intimp.2012.04.008. Epub 2012 May 2. PubMed PMID: 22561413.

[4] Lazaar AL, Sweeney LE, MacDonald AJ, Alexis NE, Chen C, Tal-Singer R.SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophilactivation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol.2011 Aug;72(2):282-93. doi: 10.1111/j.1365-2125.2011.03968.x. PubMed PMID:21426372; PubMed Central PMCID: PMC3162658.

[5] Nicholson GC, Tennant RC, Carpenter DC, Sarau HM, Kon OM, Barnes PJ, Salmon M,Vessey RS, Tal-Singer R, Hansel TT. A novel flow cytometric assay of human wholeblood neutrophil and monocyte CD11b levels: upregulation by chemokines is relatedto receptor expression, comparison with neutrophil shape change, and effects of achemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther. 2007;20(1):52-9. Epub2006 Jan 6. PubMed PMID: 16406722.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开